Evolving experience of hepatitis B virus prophylaxis in liver transplantation

Transplant Infectious Disease

Volumn 4, Issue 3, 2002, Pages 137-143

  Honaker, M R ^a   Shokouh Amiri, M H ^a   Vera, S R ^a   Alloway, R R ^a   Grewal, H P ^a   Hardinger, K L ^a   Kizilisik, A T ^a   Bagous, T ^a   Trofe, J ^a   Stratta, R J ^a   Egidi, M F ^a   Gaber, A O ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

HBV prophylaxis; HBV recurrence; Hepatitis B immunoglobulin (HBIG); Hepatitis B virus (HBV); Lamivudine (3TC); Orthotopic liver transplant (OLT)

Indexed keywords

ACICLOVIR; ANTIMETABOLITE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; FLUCONAZOLE; GANCICLOVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; NYSTATIN; PENTAMIDINE; TACROLIMUS;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; DEMOGRAPHY; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HEALTH CARE COST; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; PASSIVE IMMUNIZATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RECURRENT INFECTION; RETROSPECTIVE STUDY; SURVIVAL;

ADULT; CHEMOPREVENTION; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; INCIDENCE; LAMIVUDINE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 18744410358     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3062.2002.01012.x     Document Type: Article

References (16)

1. Maynard JE. Hepatitis B: Global importance and need for control. Vaccine 1990: 8: S18-20.
2. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994: 23: 437-455.
3. Starzl TE, Demetris AJ, Van Thiel D. Liver transplantation. N Engl J Med 1989: 321: 1092-1099.
4. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993: 329: 1842-1847.
5. Nymann T, Shokouh-Amiri MS, Vera SR, Riely CA, Alloway RR, Gaber AO. Prevention of hepatitis B recurrence with indefinite hepatitis B immune globulin (HBIG) prophylaxis after liver transplantation. Clin Transplant 1996: 10: 663-667.
6. Samuel D, Bismuth A, Mathieu D, et al. Passive immunoprophylaxis after liver transplantation in HbsAg-positive patients. Lancet 1991: 337: 813-815.
7. Devlin J, Smith HM, O'Grady GO, Portmann B, Tan KC, Williams R. Impact of immunoprophylaxis and patient selection on outcome of transplantation for HbsAg-positive liver recipients. J Hepatol 1994: 21: 204-210.
8. McGory RW, Ishitani MB, Oliverira WM, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996: 61: 1358-1364.
9. Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998: 28: 585-589.
10. Honkoop P, De Man RA, Heijtink RA, Schalm SW. Hepatitis B reactivation after lamivudine. Lancet 1995: 346: 1156-1157.
11. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneeman NM, Tyrell LJ. Mutation in. HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996: 24: 714-717.
12. Lai CL, Chien RN, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis. N Engl J Med 1998: 339: 61-68.
13. Ling R, Mutimer D, Ahmed D, et al. Selection of mutations in the hepatitis B polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996: 24: 711-713.
14. Mutimer D, Pillay D, Cook P, et al. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy. J Infect Dis 2000: 181: 713-716.
15. McCaughan GW, Spencer J, Koorey D, et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: High resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transpl Surg 1999: 5: 512-519.
16. Angus PW, McCaughan GW, Gane EJ, et al. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000: 6: 429-433.